Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Metabolic reprogramming is a hallmark of cancer, influencing tumor development and treatment resistance.
• Pancreatic Ductal Adenocarcinoma (PDAC) is notably refractory to therapies, highlighting the need for novel treatment strategies.
• Autophagy, a cellular recycling process, is frequently dysregulated in PDAC.

Purpose of the Study:

• To explore the role of metabolic reprogramming and autophagy in Pancreatic Ductal Adenocarcinoma (PDAC).
• To identify therapeutic vulnerabilities associated with aberrant autophagy in PDAC.
• To discuss the potential of combining autophagy inhibition with other treatments for PDAC.

Main Methods:

• Review of current literature on cancer metabolism and autophagy in PDAC.
• Analysis of the interplay between genetic alterations, mitochondrial metabolism, tumor microenvironment, and immune system in PDAC.
• Examination of the link between autophagy and therapeutic resistance in PDAC.

Main Results:

• Autophagy is elevated in established PDAC, supporting proliferation in nutrient-poor conditions.
• Autophagy contributes to PDAC's resistance to current therapies.
• Autophagy is interconnected with genetic factors, mitochondrial function, the tumor microenvironment, and immune responses in PDAC.

Conclusions:

• Targeting autophagy presents a viable strategy for treating PDAC, particularly in combination therapies.
• Further translational and multidisciplinary research is crucial for optimizing autophagy-targeted treatments for PDAC.
• Understanding metabolic vulnerabilities, including autophagy, is key to overcoming therapeutic resistance in PDAC.